TY - JOUR
T1 - Epithelial stem cell homeostasis in Meibomian gland development, dysfunction, and dry eye disease
AU - Tchegnon, Edem
AU - Liao, Chung Ping
AU - Ghotbi, Elnaz
AU - Shipman, Tracey
AU - Wang, Yong
AU - McKay, Renee M.
AU - Le, Lu Q.
N1 - Funding Information:
We thank all members of the Le laboratory for helpful suggestions and discussions. We also thank Patrick Charnay and Piotr Topilko at INSERM for providing mice. ET is supported by the National Cancer Institute of the NIH under award number 3R01CA166593-07S1 and received a University of Texas Southwestern Hamon Center for Regenerative Science and Medicine Fellowship Award. CPL is a recipient of the Career Development Award from the Dermatology Foundation and is also supported by Taipei Medical University (TMU109-AE1-B07), the Ministry of Science and Technology (MOST 110-2320-B-038-014-MY2), and the Ministry of Education (DP2-110-21121-01-N-12-01) in Taiwan.
Funding Information:
EG is supported by Dermatology Research Training Program T32 Grant T32AR065969. LQL held a Career Award for Medical Scientists from the Burroughs Wellcome Fund and holds the Thomas L. Shield, M.D. Professorship in Dermatology. This work was supported by funding from NIH grant R01 CA166593 to LQL.
Publisher Copyright:
© 2021, Tchegnon et al.
PY - 2021/10/22
Y1 - 2021/10/22
N2 - Dry eye disease affects over 16 million adults in the US, and the majority of cases are due to Meibomian gland dysfunction. Unfortunately, the identity of the stem cells involved in Meibomian gland development and homeostasis is not well elucidated. Here, we report that loss of Krox20, a zinc finger transcription factor involved in the development of ectoderm-derived tissues, or deletion of KROX20-expressing epithelial cells disrupted Meibomian gland formation and homeostasis, leading to dry eye disease secondary to Meibomian gland dysfunction. Ablation of Krox20-lineage cells in adult mice also resulted in dry eye disease, implicating Krox20 in homeostasis of the mature Meibomian gland. Lineage-tracing and expression analyses revealed a restricted KROX20 expression pattern in the ductal areas of the Meibomian gland, although Krox20-lineage cells generate the full, mature Meibomian gland. This suggests that KROX20 marks a stem/progenitor cell population that differentiates to generate the entire Meibomian gland. Our Krox20 mouse models provide a powerful system that delineated the identity of stem cells required for Meibomian gland development and homeostasis and can be used to investigate the factors underlying these processes. They are also robust models of Meibomian gland dysfunction-related dry eye disease, with a potential for use in preclinical therapeutic screening.
AB - Dry eye disease affects over 16 million adults in the US, and the majority of cases are due to Meibomian gland dysfunction. Unfortunately, the identity of the stem cells involved in Meibomian gland development and homeostasis is not well elucidated. Here, we report that loss of Krox20, a zinc finger transcription factor involved in the development of ectoderm-derived tissues, or deletion of KROX20-expressing epithelial cells disrupted Meibomian gland formation and homeostasis, leading to dry eye disease secondary to Meibomian gland dysfunction. Ablation of Krox20-lineage cells in adult mice also resulted in dry eye disease, implicating Krox20 in homeostasis of the mature Meibomian gland. Lineage-tracing and expression analyses revealed a restricted KROX20 expression pattern in the ductal areas of the Meibomian gland, although Krox20-lineage cells generate the full, mature Meibomian gland. This suggests that KROX20 marks a stem/progenitor cell population that differentiates to generate the entire Meibomian gland. Our Krox20 mouse models provide a powerful system that delineated the identity of stem cells required for Meibomian gland development and homeostasis and can be used to investigate the factors underlying these processes. They are also robust models of Meibomian gland dysfunction-related dry eye disease, with a potential for use in preclinical therapeutic screening.
UR - http://www.scopus.com/inward/record.url?scp=85118205807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118205807&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.151078
DO - 10.1172/jci.insight.151078
M3 - Article
C2 - 34499624
AN - SCOPUS:85118205807
SN - 2379-3708
VL - 6
JO - JCI insight
JF - JCI insight
IS - 20
M1 - e151078
ER -